A detailed history of Shelton Capital Management transactions in Repligen Corp stock. As of the latest transaction made, Shelton Capital Management holds 2,039 shares of RGEN stock, worth $306,951. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,039
Previous 2,115 3.59%
Holding current value
$306,951
Previous $266,000 13.91%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$119.79 - $167.35 $9,104 - $12,718
-76 Reduced 3.59%
2,039 $303,000
Q2 2024

Aug 13, 2024

SELL
$120.0 - $182.95 $9,360 - $14,270
-78 Reduced 3.56%
2,115 $266,000
Q1 2024

May 15, 2024

SELL
$170.78 - $208.42 $10,417 - $12,713
-61 Reduced 2.71%
2,193 $403,000
Q4 2023

Feb 14, 2024

SELL
$114.17 - $185.35 $18,153 - $29,470
-159 Reduced 6.59%
2,254 $405,000
Q3 2023

Nov 14, 2023

SELL
$138.78 - $176.51 $18,318 - $23,299
-132 Reduced 5.19%
2,413 $383,000
Q2 2023

Aug 10, 2023

SELL
$138.42 - $180.31 $13,426 - $17,490
-97 Reduced 3.67%
2,545 $360,000
Q4 2022

Feb 13, 2023

SELL
$162.42 - $220.56 $14,292 - $19,409
-88 Reduced 3.22%
2,642 $447,000
Q2 2020

Aug 12, 2020

SELL
$94.33 - $140.48 $20,186 - $30,062
-214 Reduced 7.27%
2,730 $337,000
Q4 2019

Feb 11, 2020

SELL
$73.84 - $93.08 $74,209 - $93,545
-1,005 Reduced 25.45%
2,944 $272,000
Q2 2019

Aug 14, 2019

BUY
$54.2 - $85.95 $201,407 - $319,390
3,716 Added 1594.85%
3,949 $339,000
Q1 2019

May 10, 2019

SELL
$49.45 - $62.8 $183,756 - $233,364
-3,716 Reduced 94.1%
233 $3.95 Million
Q4 2018

Jan 31, 2019

BUY
$48.26 - $68.88 $8,638 - $12,329
179 Added 4.75%
3,949 $208,000
Q3 2018

Nov 14, 2018

BUY
$46.8 - $58.97 $176,436 - $222,316
3,770 New
3,770 $209,000

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $8.35B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Shelton Capital Management Portfolio

Follow Shelton Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shelton Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Shelton Capital Management with notifications on news.